Blog Read the latest perspectives from our team of subject matter experts and others FDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development Global Impact HCP Volunteers KOL Engagement Provider Data Research Post Industries:Commercialization Global Impact Payors Pharmaceutical & Biotechnology Provider Data Research Diversity & InclusionDrug DevelopmentFDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading → Read the articleyes Diversity & InclusionDrug DevelopmentThe Opportunities and Challenges of Improving Health Equity with Expert Daniel PerezThe pursuit of health equity has many obstacles. Achieving a state where everyone has fair and equitable access to healthcare is a massive endeavor with many stakeholders. It requires addressing… Continue reading → Read the articleno Diversity & InclusionDrug DevelopmentEthics and Equity in Clinical Trials & FDA Diversity Guidance PrepClinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of… Continue reading → Read the articleno Artificial IntelligenceKOL EngagementProvider DataA Holistic Approach to Measuring ImpactMedical Affairs plays an essential role in evidence-based medicine, disease education, and driving better outcomes. Their knowledge is crucial as medications become more specialized and complex. They enable healthcare… Continue reading → Read the articleno Artificial IntelligenceCommercializationDiversity & InclusionDrug DevelopmentKOL EngagementProvider DataResearchTrials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentSix Possible Implications of Biden’s Executive Order on AI for Life SciencesThe life sciences sector stands on the brink of a new era marked by the confluence of artificial intelligence (AI) and biomedicine. With President Biden’s recent Executive Order on AI,… Continue reading → Read the articleno1234›»